Physician profile
David Lynch
NPI 1093373987
$2,321.22
in general payments reported to CMS, 2019-2025
22 companies · $625 in 2025
The $625 reported for 2025 was more than what 77% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $314 · 2020: $152 · 2021: $36.03 · 2022: $171 · 2023: $387 · 2024: $636 · 2025: $625.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,648.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,648.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $437.01 | 2019-2025 | Breztri |
| Novo Nordisk INC | $418.09 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $272.83 | 2022-2024 | Zepbound, Jardiance |
| Axsome Therapeutics, INC. | $191.51 | 2025 | Auvelity |
| Otsuka America Pharmaceutical, INC. | $153.99 | 2019 | |
| Ethicon INC. | $137.79 | 2023 | Monarch Platform |
| Phathom Pharmaceuticals, INC. | $111.41 | 2024 | Voquezna |
| Pfizer INC. | $108.56 | 2019-2025 | |
| Astellas Pharma US INC | $96.88 | 2023-2025 | Veozah |
| Abbvie INC. | $77.78 | 2022-2025 | |
| Exact Sciences Corporation | $51.41 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Horizon Therapeutics Plc | $45.35 | 2022 | |
| Inspire Medical Systems, INC. | $38.34 | 2025 | Inspire |
| Tactile Systems Technology INC | $26.61 | 2024 | Entre Plus, Flexitouch Plus |
| Allergan, INC. | $25.66 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almatica Pharma LLC | $24.69 | 2024 | Loreev Xr |
| Amarin Pharma, INC. | $20.56 | 2019 | |
| Novartis Pharmaceuticals Corporation | $19.60 | 2019 | |
| Neurocrine Biosciences, INC. | $18.78 | 2019 | |
| Echosens North America, INC. | $16.05 | 2024 | Fibroscan |
| Vertex Pharmaceuticals Incorporated | $14.79 | 2025 | |
| Merck Sharp & Dohme LLC | $13.53 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Lynch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.